Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

1. Esketamine (Spravato) - In combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin–norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant major depressive disorder, who have not responded to at least two differ

Esketamine (Spravato) - In combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin–norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant major depressive disorder, who have not responded to at least two differ 1 Published 7 September 2020 SMC2258 esketamine 28mg nasal spray, solution (Spravato®) Janssen-Cilag Ltd 7 August 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area (...) Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission esketamine (Spravato®) is accepted for use within NHSScotland. Indication under review: In combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants

2020 Scottish Medicines Consortium

2. Reducing the Risk for Postpartum Depression in Adolescent Mothers: A Randomized Controlled Trial

Reducing the Risk for Postpartum Depression in Adolescent Mothers: A Randomized Controlled Trial Reducing the Risk for Postpartum Depression in Adolescent Mothers: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health (...) at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Obstet Gynecol Actions . 2020 Sep;136(3):613-621. doi: 10.1097/AOG.0000000000004003. Reducing the Risk for Postpartum Depression in Adolescent Mothers

2020 EvidenceUpdates

3. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study

Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) : 10.1176/appi.ajp.2020.19080844. Online ahead of print. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliation 1 Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry

2020 EvidenceUpdates

4. Effect of a Collaborative Care Model on Depressive Symptoms and Glycated Hemoglobin, Blood Pressure, and Serum Cholesterol Among Patients With Depression and Diabetes in India: The INDEPENDENT Randomized Clinical Trial. (Abstract)

Effect of a Collaborative Care Model on Depressive Symptoms and Glycated Hemoglobin, Blood Pressure, and Serum Cholesterol Among Patients With Depression and Diabetes in India: The INDEPENDENT Randomized Clinical Trial. Mental health comorbidities are increasing worldwide and worsen outcomes for people with diabetes, especially when care is fragmented.To assess whether collaborative care vs usual care lowers depressive symptoms and improves cardiometabolic indices among adults with diabetes (...) of patients at 24 months who had at least a 50% reduction in Symptom Checklist Depression Scale (SCL-20) scores (range, 0-4; higher scores indicate worse symptoms) and a reduction of at least 0.5 percentage points in HbA1c, 5 mm Hg in SBP, or 10 mg/dL in LDL cholesterol. Prespecified secondary outcomes were percentage of patients at 12 and 24 months who met treatment targets (HbA1c <7.0%, SBP <130 mm Hg, LDL cholesterol <100 mg/dL [<70 mg/dL if prior cardiovascular disease]) or had improvements

2020 JAMA

5. Behavioural activation therapy for depression in adults with non-communicable diseases. (Abstract)

Behavioural activation therapy for depression in adults with non-communicable diseases. Depression is common in people with non-communicable diseases (NCDs) such as cardiovascular disease, diabetes, cancer, and chronic respiratory conditions. The co-existence of depression and NCDs may affect health behaviours, compliance with treatment, physiological factors, and quality of life. This in turn is associated with worse outcomes for both conditions. Behavioural activation is not currently (...) indicated for the treatment of depression in this population in the UK, but is increasingly being used to treat depression in adults.To examine the effects of behavioural activation compared with any control group for the treatment of depression in adults with NCDs. To examine the effects of behavioural activation compared with each control group separately (no treatment, waiting list, other psychological therapy, pharmacological treatment, or any other type of treatment as usual) for the treatment

2020 Cochrane

6. Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. (Abstract)

Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. Low levels of 25-hydroxyvitamin D have been associated with higher risk for depression later in life, but there have been few long-term, high-dose large-scale trials.To test the effects of vitamin D3 supplementation on late-life depression risk and mood scores.There were 18 353 men and women aged 50 years or older (...) in the VITAL-DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) ancillary study to VITAL, a randomized clinical trial of cardiovascular disease and cancer prevention among 25 871 adults in the US. There were 16 657 at risk for incident depression (ie, no depression history) and 1696 at risk for recurrent depression (ie, depression history but no treatment for depression within the past 2 years). Randomization occurred from November 2011 through March 2014; randomized treatment ended

2020 JAMA

7. Implanted vagus nerve stimulation for treatment-resistant depression

Implanted vagus nerve stimulation for treatment-resistant depression Implanted vagus nerve stimulation for treatment-resistant depression Interventional procedures guidance Published: 12 August 2020 www.nice.org.uk/guidance/ipg679 Your responsibility Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account (...) Recommendations Recommendations 1.1 Evidence on the safety of implanted vagus nerve stimulation for treatment- resistant depression raises no major safety concerns, but there are frequent, well-recognised side effects. Evidence on its efficacy is limited in quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE website. 1.2 Clinicians wishing to do implanted vagus nerve

2020 National Institute for Health and Clinical Excellence - Interventional Procedures

8. Effectiveness of cognitive behavioural therapy for perinatal depression: A systematic review and meta-analysis

Effectiveness of cognitive behavioural therapy for perinatal depression: A systematic review and meta-analysis Effectiveness of cognitive behavioural therapy for perinatal depression: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get (...) there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review J Clin Nurs Actions . 2020 Sep;29(17-18):3170-3182. doi: 10.1111/jocn.15378. Epub 2020 Jul 15. Effectiveness of cognitive behavioural therapy for perinatal depression: A systematic review and meta-analysis

2020 EvidenceUpdates

9. Association of Suicide Prevention Interventions With Subsequent Suicide Attempts, Linkage to Follow-up Care, and Depression Symptoms for Acute Care Settings: A Systematic Review and Meta-analysis

Association of Suicide Prevention Interventions With Subsequent Suicide Attempts, Linkage to Follow-up Care, and Depression Symptoms for Acute Care Settings: A Systematic Review and Meta-analysis Association of Suicide Prevention Interventions With Subsequent Suicide Attempts, Linkage to Follow-up Care, and Depression Symptoms for Acute Care Settings: A Systematic Review and Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete (...) ;e201586. doi: 10.1001/jamapsychiatry.2020.1586. Online ahead of print. Association of Suicide Prevention Interventions With Subsequent Suicide Attempts, Linkage to Follow-up Care, and Depression Symptoms for Acute Care Settings: A Systematic Review and Meta-analysis , , , , , , , , Affiliations Expand Affiliations 1 PolicyLab, Center for Pediatric Clinical Effectiveness, Division of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 2 Department of Pediatrics

2020 EvidenceUpdates

10. Pharmacological treatment of depression in people with a primary brain tumour. (Abstract)

Pharmacological treatment of depression in people with a primary brain tumour. This is the second updated version of the Cochrane Review published in Issue 3, 2010 and first updated in Issue 5, 2013. People with a primary brain tumour often experience depression, for which drug treatment may be prescribed. However, they are also at high risk of epileptic seizures, cognitive impairment, and fatigue, all of which are potential adverse side effects of antidepressants. The benefit, or harm (...) , of pharmacological treatment of depression in people with a primary brain tumour is unclear.To assess the benefits and harms of pharmacological treatment of depression in people with a primary brain tumour.We updated the search to include CENTRAL, MEDLINE, Embase, and PsycINFO to September 2019. As in the original review, we also handsearched Neuro-Oncology, Journal of Neuro-Oncology, Journal of Neurology, Neurosurgery and Psychiatry, and Journal of Clinical Oncology: for the current update we handsearched

2020 Cochrane

11. Behavioural activation therapy for depression in adults. (Abstract)

Behavioural activation therapy for depression in adults. Behavioural activation is a brief psychotherapeutic approach that seeks to change the way a person interacts with their environment. Behavioural activation is increasingly receiving attention as a potentially cost-effective intervention for depression, which may require less resources and may be easier to deliver and implement than other types of psychotherapy.To examine the effects of behavioural activation compared with other (...) psychological therapies for depression in adults. To examine the effects of behavioural activation compared with medication for depression in adults. To examine the effects of behavioural activation compared with treatment as usual/waiting list/placebo no treatment for depression in adults.We searched CCMD-CTR (all available years), CENTRAL (current issue), Ovid MEDLINE (1946 onwards), Ovid EMBASE (1980 onwards), and Ovid PsycINFO (1806 onwards) on the 17 January 2020 to identify randomised controlled

2020 Cochrane

12. Effectiveness of a Guided Web-Based Self-help Intervention to Prevent Depression in Patients With Persistent Back Pain: The PROD-BP Randomized Clinical Trial

Effectiveness of a Guided Web-Based Self-help Intervention to Prevent Depression in Patients With Persistent Back Pain: The PROD-BP Randomized Clinical Trial Effectiveness of a Guided Web-Based Self-help Intervention to Prevent Depression in Patients With Persistent Back Pain: The PROD-BP Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation JAMA Psychiatry Actions . 2020 May 27;e201021. doi: 10.1001/jamapsychiatry.2020.1021. Online ahead of print. Effectiveness of a Guided Web-Based Self-help Intervention to Prevent Depression in Patients With Persistent Back Pain: The PROD-BP Randomized Clinical Trial , , , , , , , , Affiliations Expand Affiliations 1 Institute

2020 EvidenceUpdates

13. Psychotherapy for Depression Across Different Age Groups: A Systematic Review and Meta-analysis

Psychotherapy for Depression Across Different Age Groups: A Systematic Review and Meta-analysis Psychotherapy for Depression Across Different Age Groups: A Systematic Review and Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology (...) Actions Cite Share Permalink Copy Page navigation JAMA Psychiatry Actions . 2020 Mar 18;77(7):694-702. doi: 10.1001/jamapsychiatry.2020.0164. Online ahead of print. Psychotherapy for Depression Across Different Age Groups: A Systematic Review and Meta-analysis , , , , , , , Affiliations Expand Affiliations 1 Department of Clinical, Neuro, and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. 2 Massachusetts General Hospital

2020 EvidenceUpdates

14. Acceptance and commitment therapy for the treatment of depression in persons with physical disability: a randomized controlled trial

Acceptance and commitment therapy for the treatment of depression in persons with physical disability: a randomized controlled trial Acceptance and commitment therapy for the treatment of depression in persons with physical disability: a randomized controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes (...) of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions . 2020 Jul;34(7):938-947. doi: 10.1177/0269215520923135. Epub 2020 May 31. Acceptance and commitment therapy for the treatment of depression in persons with physical disability: a randomized controlled trial , Affiliations Expand Affiliation 1 Department of Clinical Psychology, University of Kurdistan, Sanandaj, Iran. PMID: 32476482 DOI: Item in Clipboard

2020 EvidenceUpdates

15. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial

Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National (...) RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation JAMA Psychiatry Actions . 2020 Jun 3;e201214. doi: 10.1001/jamapsychiatry.2020.1214. Online ahead of print. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 The Institute for Mental and Physical Health and Clinical Translation Strategy Research Centre, Deakin University School of Medicine, Geelong

2020 EvidenceUpdates

16. Harmonized Outcome Measures for Use in Depression Patient Registries and Clinical Practice. (Abstract)

Harmonized Outcome Measures for Use in Depression Patient Registries and Clinical Practice. Major depressive disorder is a common mental health condition that affects an estimated 16.2 million adults and 3.1 million adolescents in the United States. Yet, a lack of uniformity remains in measurements and monitoring for depression both in clinical practice and in research settings. This project aimed to develop a minimum set of standardized outcome measures relevant to both patients and clinicians (...) that can be collected in depression registries and clinical practice. Twenty-nine depression registries and related data collection efforts were identified and invited to submit outcome measures. Additional measures were identified through literature searches and reviews of quality measures. A multistakeholder panel representing clinicians; payers; government agencies; industry; and medical specialty, health care quality, and patient advocacy organizations categorized the 27 identified measures using

2020 Annals of Internal Medicine

17. Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis. (Abstract)

Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis. The Patient Health Questionnaire depression module (PHQ-9) is a 9-item self-administered instrument used for detecting depression and assessing severity of depression. The Patient Health Questionnaire-2 (PHQ-2) consists of the first 2 items of the PHQ-9 (which assess the frequency of depressed mood and anhedonia) and can be used as a first step to identify (...) patients for evaluation with the full PHQ-9.To estimate PHQ-2 accuracy alone and combined with the PHQ-9 for detecting major depression.MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, PsycINFO, and Web of Science (January 2000-May 2018).Eligible data sets compared PHQ-2 scores with major depression diagnoses from a validated diagnostic interview.Individual participant data were synthesized with bivariate random-effects meta-analysis to estimate pooled sensitivity and specificity of the PHQ-2

2020 JAMA

18. Cognitive training interventions and depression in mild cognitive impairment and dementia: a systematic review and meta-analysis of randomized controlled trials

Cognitive training interventions and depression in mild cognitive impairment and dementia: a systematic review and meta-analysis of randomized controlled trials Cognitive Training Interventions and Depression in Mild Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Age Ageing Actions . 2020 May 6;afaa063. doi: 10.1093/ageing/afaa063. Online ahead of print. Cognitive Training Interventions and Depression in Mild Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , , , , , Affiliations Expand Affiliations 1 Department

2020 EvidenceUpdates

19. Effect of Adding a Work-Focused Intervention to Integrated Care for Depression in the Veterans Health Administration: A Randomized Clinical Trial (Full text)

Effect of Adding a Work-Focused Intervention to Integrated Care for Depression in the Veterans Health Administration: A Randomized Clinical Trial Effect of Adding a Work-Focused Intervention to Integrated Care for Depression in the Veterans Health Administration: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation JAMA Netw Open Actions . 2020 Feb 5;3(2):e200075. doi: 10.1001/jamanetworkopen.2020.0075. Effect of Adding a Work-Focused Intervention to Integrated Care for Depression in the Veterans Health Administration: A Randomized Clinical Trial , , , , Affiliations Expand Affiliations 1 Program on Health, Work and Productivity, Institute for Clinical

2020 EvidenceUpdates PubMed abstract

20. Space from Depression for treating adults with depression

Space from Depression for treating adults with depression Space from Depression for treating adults with depression Medtech innovation briefing Published: 7 May 2020 www.nice.org.uk/guidance/mib215 pathways Expert panel conclusions Expert panel conclusions • Therapist and Improving Access to Psychological Therapies (IAPT) service feedback on Space from Depression (SilverCloud) was generally positive. The evaluation data and user feedback showed that it was an effective treatment for some users (...) . • The IAPT expert panel therefore concluded that the case for adoption is partially supported case for adoption is partially supported for Space from Depression. They noted that Space from Depression is suitable for use in IAPT services when: - there is monitoring to identify and help people who stop engaging with the service - there is flexibility about how much the therapist and service user can communicate - there are clear plans to help service providers put Space from Depression into practice. Panel

2020 National Institute for Health and Clinical Excellence - Advice